Market Turmoil: Regeneron Takes a Hit After FDA's CRL
- June 27th, 2023
- 373 views
Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) tumbled more than 8% during intraday trading in response to the company receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA).
The CRL was issued for the Biologics License Application (BLA) of aflibercept 8 mg, intended for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The FDA's decision was based on an ongoing review of inspection findings at a third-party filler, unrelated to any concerns about the drug's clinical efficacy, safety, trial design, labeling, or manufacturing.
According to Regeneron, no further clinical data or trials have been requested and it remains committed to collaborating closely with the FDA and the third-party filler to expedite the availability of aflibercept 8 mg for patients with wAMD, DME, and DR.
Currently, $REGN is trading at $720.00, reflecting a decline of $64.38 (8.21%) following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login